301 related articles for article (PubMed ID: 19456205)
1. Cellular immunotherapy for ovarian cancer.
Cannon MJ; O'Brien TJ
Expert Opin Biol Ther; 2009 Jun; 9(6):677-88. PubMed ID: 19456205
[TBL] [Abstract][Full Text] [Related]
2. New Approaches for Immune Directed Treatment for Ovarian Cancer.
Hardwick N; Frankel PH; Cristea M
Curr Treat Options Oncol; 2016 Mar; 17(3):14. PubMed ID: 26942589
[TBL] [Abstract][Full Text] [Related]
3. Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence.
Wefers C; Lambert LJ; Torensma R; Hato SV
Gynecol Oncol; 2015 May; 137(2):335-42. PubMed ID: 25727651
[TBL] [Abstract][Full Text] [Related]
4. Leveraging epigenetics to enhance the efficacy of cancer-testis antigen: a potential candidate for immunotherapy.
Gupta R; Jit BP; Kumar S; Mittan S; Tanwer P; Ray MD; Mathur S; Perumal V; Kumar L; Rath GK; Sharma A
Epigenomics; 2022 Jul; 14(14):865-886. PubMed ID: 35872653
[TBL] [Abstract][Full Text] [Related]
5. Ovarian cancer biology and immunotherapy.
Latha TS; Panati K; Gowd DS; Reddy MC; Lomada D
Int Rev Immunol; 2014 Oct; 33(5):428-40. PubMed ID: 24911597
[TBL] [Abstract][Full Text] [Related]
6. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
7. Prospects and challenges for immunotherapy of ovarian cancer--what can we learn from the tumor microenvironment?
Chiriva-Internati M; Cobos E; Cannon MJ
Int Rev Immunol; 2011; 30(2-3):67-70. PubMed ID: 21557634
[TBL] [Abstract][Full Text] [Related]
8. The immunotherapy of patients with ovarian cancer.
Hwu P; Freedman RS
J Immunother; 2002; 25(3):189-201. PubMed ID: 12000860
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in ovarian cancer.
Odunsi K
Ann Oncol; 2017 Nov; 28(suppl_8):viii1-viii7. PubMed ID: 29232467
[TBL] [Abstract][Full Text] [Related]
10. Immunological treatment of ovarian cancer.
Cannon MJ; Santin AD; O'Brien TJ
Curr Opin Obstet Gynecol; 2004 Feb; 16(1):87-92. PubMed ID: 15128013
[TBL] [Abstract][Full Text] [Related]
11. The impact of T-cell immunity on ovarian cancer outcomes.
Nelson BH
Immunol Rev; 2008 Apr; 222():101-16. PubMed ID: 18363996
[TBL] [Abstract][Full Text] [Related]
12. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
[TBL] [Abstract][Full Text] [Related]
13. Understanding dendritic cell immunotherapy in ovarian cancer.
Drakes ML; Stiff PJ
Expert Rev Anticancer Ther; 2016 Jun; 16(6):643-52. PubMed ID: 27078511
[TBL] [Abstract][Full Text] [Related]
14. Opportunities in immunotherapy of ovarian cancer.
Coukos G; Tanyi J; Kandalaft LE
Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i11-i15. PubMed ID: 27141063
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for ovarian cancer: recent advances and perspectives.
Zsiros E; Tanyi J; Balint K; Kandalaft LE
Curr Opin Oncol; 2014 Sep; 26(5):492-500. PubMed ID: 25036883
[TBL] [Abstract][Full Text] [Related]
16. Past, present and future targets for immunotherapy in ovarian cancer.
Schwab CL; English DP; Roque DM; Pasternak M; Santin AD
Immunotherapy; 2014; 6(12):1279-93. PubMed ID: 25524384
[TBL] [Abstract][Full Text] [Related]
17. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
Sarivalasis A; Boudousquié C; Balint K; Stevenson BJ; Gannon PO; Iancu EM; Rossier L; Martin Lluesma S; Mathevet P; Sempoux C; Coukos G; Dafni U; Harari A; Bassani-Sternberg M; Kandalaft LE
J Transl Med; 2019 Nov; 17(1):391. PubMed ID: 31771601
[TBL] [Abstract][Full Text] [Related]
18. Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?
Martin-Lluesma S; Graciotti M; Grimm AJ; Boudousquié C; Chiang CL; Kandalaft LE
Curr Opin Biotechnol; 2020 Oct; 65():190-196. PubMed ID: 32334152
[TBL] [Abstract][Full Text] [Related]
19. Antigen-specific active immunotherapy for ovarian cancer.
Paijens ST; Leffers N; Daemen T; Helfrich W; Boezen HM; Cohlen BJ; Melief CJ; de Bruyn M; Nijman HW
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD007287. PubMed ID: 30199097
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy in Ovarian Cancer.
Wang W; Liu JR; Zou W
Surg Oncol Clin N Am; 2019 Jul; 28(3):447-464. PubMed ID: 31079799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
